Lv3
390 积分 2025-12-04 加入
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy
6天前
已完结
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug–Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype
21天前
已完结
Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation
22天前
已完结
Left Atrial Volume Index: A Predictor of Adverse Outcome in Patients With Hypertrophic Cardiomyopathy
22天前
已完结
Role of abnormal sarcoplasmic reticulum function in atrial fibrillation
22天前
已关闭
Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
22天前
已完结
Atrial Cardiomyopathy: An Unexplored Limb of Virchow's Triad for AF Stroke Prophylaxis
22天前
已完结
Mavacamten-like myosin inhibitor MYK-581 reduces the risk of atrial fibrillation induction in a murine model of hypertrophic cardiomyopathy
1个月前
已完结
The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials
1个月前
已完结
Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis
1个月前
已完结
皖公网安备34019202002308
